Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Therapure Biopharma to Acquire Plasma Protein Purification Technology

Published: Monday, December 09, 2013
Last Updated: Sunday, December 08, 2013
Bookmark and Share
Therapure and Upfront have entered into an agreement.

Therapure Biopharma Inc. and Upfront Chromatography A/S have announced that they have entered into an agreement for Therapure to acquire the assets and associated business related to human plasma fractionation from Upfront.

Upfront has developed over the last 15 years, a proprietary protein purification technology, based on Expanded Bed Adsorption (EBA) chromatography which offers significant advantages over to other purification technologies.

As a result of the acquisition, Therapure gains exclusive rights for the commercialization of the Upfront technology relevant to the human plasma fractionation field. Therapure will continue to develop and market this technology under the new trademark PlasmaCap EBA.

Nick Green, CEO of Therapure, commented: “The acquisition of the PlasmaCap EBA technology is an important addition to Therapure’s purification portfolio. With PlasmaCap EBA, Therapure now possesses a technology to capture therapeutic plasma proteins that is highly efficient and less damaging to the end product compared to conventional methods of fractionation. Ultimately PlasmaCap EBA allows for a more cost-effective process to manufacture plasma proteins. Therapure has established an excellent reputation as a biologics contract development and manufacturing organization (CDMO) with integrated services including plasma protein purification. The acquisition of this technology will further support Therapure’s reputation as a leader in the biologics manufacturing sector in general, and as a global leader in terms of plasma protein purification. We feel strongly that this technology can add significant value to our clients as they seek to optimize their manufacturing processes and associated economics.”

Upfront divested their pharmaceutical business unit in April 2010 to DSM Biologics, and is now focusing on their BioMine business line, where the technology is offered to the food/feed ingredients business for extraction of food grade proteins.

“We see this additional divestment of our technology to Therapure as a major milestone for Upfront”, commented Michael Pålsson, CEO of Upfront. “It is yet another significant blue-stamp of our technology, driven by its value creation in the capture of high value proteins. We are now ready to focus 100% on our BioMine business which aims to valorize under-utilized side and waste streams from the food, feed and biofuel industries. There is a broad range of food and feed industries in the world with large volumes of side and waste streams containing valuable proteins. We are able to help these manufacturers get more value out of these streams, and at the same time we see a growing, global need for alternative protein sources to feed the world’s population.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Therapure Biopharma Awarded US Government Contract
DoD contract to manufacture materials for anti-nerve gas agent.
Thursday, June 20, 2013
Scientific News
Retractable Protein Nanoneedles
The ability to control the transfer of molecules through cellular membranes is an important function in synthetic biology; a new study from researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering and Harvard Medical School (HMS) introduces a novel mechanical method for controlling release of molecules inside cells.
Leukemia’s Surroundings Key to its Growth
Researchers at The University of Texas at Austin have discovered that a type of cancer found primarily in children can grow only when signaled to do so by other nearby cells that are noncancerous.
Common Cell Transformed into Master Heart Cell
By genetically reprogramming the most common type of cell in mammalian connective tissue, researchers at the University of Wisconsin—Madison have generated master heart cells — primitive progenitors that form the developing heart.
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Genetic Mutation that Prevents Diabetes Complications
The most significant complications of diabetes include diabetic retinal disease, or retinopathy, and diabetic kidney disease, or nephropathy. Both involve damaged capillaries.
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Improving Regenerative Medicine
Lab-created stem cells may lack key characteristics, UCLA research finds.
Tick Genome Reveals Secrets of a Successful Bloodsucker
NIH has announced that decipher the genome of the blacklegged tick which could lead to new tick control methods.
"Dark Side" of the Transcriptome
New approach to quantifying gene "read-outs" reveals important variations in protein synthesis and has implications for understanding neurodegenerative diseases.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!